Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Esther Bowie MD
Esther M. Bowie MD Advisory Board
Myron Yanoff MD
Myron Yanoff MD Editor-in-Chief
Joseph Ortiz MD
Joseph M. Ortiz MD Advisory Board
See All Experts
featured
Published in Eye Care

Expert Opinion / Commentary · December 10, 2024

2024 Top Story in Eye Care: Faricimab and Gene Therapy in Retinal Diseases

Weiye Li MD, PhD

 

 Save  Recommend
 Share

Additional Info

  1. Khanani AM, Kotecha A, Chang A, et al. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2. Ophthalmology. 2024;131(8):914-926.
  2. Wong TY, Haskova Z, Asik K, et al. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials. Ophthalmology. 2024;131(6):708–723.
  3. Desideri LF, Traverso CE, Nicolò M, et al. Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration. Pharmaceutics. 2023;15(5):1413.
  4. Javaheri M, Khan H, Aziz AA, et al. Real-World Efficacy and Safety of Faricimab in nAMD: Two-Year Results of the TRUCKEE Study. Paper presented at: American Academy of Ophthalmology (AAO) 2024 Annual Meeting; October 18–21, 2024; Chicago, IL. Abstract PO585.
  5. Durrani AF, Momenaei B, Wakabayashi T, et al. Conversion to Faricimab After Prior Antivascular Endothelial Growth Factor Therapy for Persistent Diabetic Macular Oedema. Br J Ophthalmol. 2024;108(9):1257–1262.
  6. Dibas A, Batabyal S, Kim S, et al. Efficacy of Intravitreal Multi-Characteristic Opsin (MCO-010) Optogenetic Gene Therapy in a Mouse Model of Leber Congenital Amaurosis. J Ocul Pharmacol Ther. 2024 Oct 23. doi: 10.1089/jop.2024.0084. Online ahead of print.
  7. PracticeUpdate Editorial Team. AAO 2024: Gene Therapy Improves Vision in Retinitis Pigmentosa (HealthDay News). PracticeUpdate Eye Care. 2024 Oct 28. Accessed November 12, 2024.

Further Reading

Most Read This Week

Recently Updated